|
English
|
正體中文
|
简体中文
|
0
|
|
???header.visitor??? :
53088521
???header.onlineuser??? :
962
???header.sponsordeclaration???
|
|
|
|
???tair.name??? >
???browser.page.title.author???
|
"beck j t"???jsp.browse.items-by-author.description???
Showing items 1-3 of 3 (1 Page(s) Totally)
1
View [10|25|50] records per page
| 臺大學術典藏 |
2021-01-05T00:56:27Z |
Long-term effects of crizotinib in ALK-positive tumors (excluding NSCLC): A phase 1b open-label study
|
Braiteh F.; Zhang L.; Orlov S.; Gambacorti-Passerini C.; Huang H.; Esaki T.; Horibe K.; Ahn J.-S.; Beck J.T.; Edenfield W.J.; Shi Y.; Taylor M.; Tamura K.; Van Tine B.A.; SHANG-JU WU; Paolini J.; Selaru P.; Kim T.M. |
| 臺大學術典藏 |
2020-03-23T07:18:53Z |
Paclitaxel with inhibitor of apoptosis antagonist, LCL161, for localized triple-negative breast cancer, prospectively stratified by gene signature in a biomarker-driven neoadjuvant trial
|
Bardia A.; Bardia A.;Parton M.;Kummel S.;Estevez L.G.;Chiun-Sheng Huang;Cortes J.;Ruiz-Borrego M.;Telli M.L.;Martin-Martorell P.;Lopez R.;Beck J.T.;Ismail-Khan R.;Chen S.-C.;Hurvitz S.A.;Mayer I.A.;Carreon D.;Cameron S.;Liao S.;Baselga J.;Kim S.-B.; Parton M.; Kummel S.; Estevez L.G.; CHIUN-SHENG HUANG; Cortes J.; Ruiz-Borrego M.; Telli M.L.; Martin-Martorell P.; Lopez R.; Beck J.T.; Ismail-Khan R.; Chen S.-C.; Hurvitz S.A.; Mayer I.A.; Carreon D.; Cameron S.; Liao S.; Baselga J.; Kim S.-B. |
| 國立臺灣大學 |
2015 |
Synergy of LCL161, an antagonist of inhibitor of apoptosis proteins (IAPs), with paclitaxel in a gene expression signature-enriched cohort of triple-negative breast cancer (TNBC)
|
Bardia, A.; Cameron, J. S.; Venkatesan, K.; Robinson, D.; Porter, D.; Kim, S. B.; Parton, M.; Kuemmel, S.; Estevez, L. G.; Huang, C. S.; Cortes Castan, J.; Ruiz-Borrego, M.; Telli, M.; Martin Martorell, P.; Lopez, R.; Beck, J. T.; Ismail-Khan, R.; Chen, S. C.; Hurvitz, S.; Mayer, I.; 黃俊升 |
Showing items 1-3 of 3 (1 Page(s) Totally)
1
View [10|25|50] records per page
|
